AgomAb Therapeutics NV (AGMB) fair value analysis
Nasdaq · Updated 2026-10-19
AGMB price how computed
Valuation status
Reports in EURAGMB reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for AGMB until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $8.65
- Sector
- Healthcare
- 12-month range
- $8.65–$16.21
- Market cap
- $426M
- From 52-week high
- -46.6%
- Shares outstanding
- 49.2M
- Rank in Healthcare by quality score
- #216 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
AgomAb Therapeutics NV is a biopharmaceutical company developing therapeutic antibodies focused on treating diseases related to immune and inflammatory conditions. The company is based in the Netherlands and operates as a Nasdaq-listed entity in the Healthcare sector.
AGMB currently ranks #216 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $426M
- Debt / equity
- 0.00
- Shares outstanding
- 49.2M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 23 · oversold
Earnings how computed
- Last 1 quarters vs consensus
- 1 beat, 0 missed
- Quarter by quarter
- 2026-03 ▲ beat (+7.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 0 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $37.7
- Target vs last price
- +335.8%
What our data shows for AGMB
- Shares are trading in the lower third of their 12-month price range of $8.65–$16.21.
- The 14-day relative strength index sits at an oversold 23.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- AGMB's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the AGMB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for AGMB showed a shift in the Relative Strength Index zone this week, moving from neutral to oversold territory. The current valuation verdict for the healthcare sector company remains awaiting full valuation.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is AGMB stock undervalued?
AGMB reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for AGMB until same-currency inputs are available.
What is AGMB's TickrTrends verdict?
AGMB is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does AGMB compare to other Healthcare stocks?
AGMB ranks #216 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is AGMB overbought or oversold?
AGMB's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does AGMB usually beat earnings estimates?
Over its last 1 reported quarters AGMB beat the consensus estimate 1 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AGMB?
Of 7 analysts covering AGMB, 7 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $37.7 (+335.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.